Open Source or Commercial? Lasse Goerlitz, CLC Bio, Talks BioinformaticsSubmitted by Ayanna Monteverdi on Wed, 05/29/2013 - 09:50
Podcast brought to you by: Ingenuity Variant Analysis - Identify causal variants from human sequencing data in just hours.
Lasse Goerlitz, VP of Communications, CLC Bio
Bio and Contact Info
Listen (5:16) Highest demand coming from agro
Listen (3:06) What is holding back the adoption of genomic medicine?
Listen (4:03) A commercial platform with plug-ins
Listen (3:37) Open source vs commercial software
Listen (4:40) The all-in-one guys
Listen (5:56) Genomics in Europe
The repeating trend from industry to industry is for software to go from fragmented, custom applications toward larger dominant platforms. It's still the early days for bioinformatics, and just who the dominant platforms of the future will be remain unknown. Will they be open source, public platforms or commercial platforms?
CLC Bio, a bioinformatics company has been working on the solution for eight years now and hopes that their platform which works with many different plug-ins will become number one for biologists around the world. In today's show, CLC's VP of Communications, Lasse Goerlitz, talks about their platform and trends in genomics. Currently their heaviest users are in ag bio, but the demand from the clinic is rising. We conclude with a discussion of differences between Europe and the US in the genomics space.